A Comparison of the Effects of Carvedilol and Metoprolol on Well-Being, Morbidity, and Mortality (the “Patient Journey”) in Patients With Heart Failure: A Report From the Carvedilol Or Metoprolol European Trial (COMET)
- 18 April 2006
- journal article
- research article
- Published by Elsevier in Journal of the American College of Cardiology
- Vol. 47 (8) , 1603-1611
- https://doi.org/10.1016/j.jacc.2005.11.069
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- The impact of chronic heart failure on health-related quality of life data acquired in the baseline phase of the CARE-HF studyEuropean Journal of Heart Failure, 2005
- Baseline characteristics of patients recruited into the CARE-HF studyEuropean Journal of Heart Failure, 2005
- A Description of the Clinical Characteristics at Baseline of Patients Recruited into the Carvedilol or Metoprolol European Trial (COMET)Cardiovascular Drugs and Therapy, 2004
- Combined endpoints: can we use them?Statistics in Medicine, 2002
- A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart FailureNew England Journal of Medicine, 2001
- Proposal for a new clinical end point to evaluate the efficacy of drugs and devices in the treatment of chronic heart failureJournal of Cardiac Failure, 2001
- Costs and effects of enalapril therapy in patients with symptomatic heart failure: An economic analysis of the studies of left ventricular dysfunction (SOLVD) treatment trialJournal of Cardiac Failure, 1995
- Quality of life among 5,025 patients with left ventricular dysfunction randomized between placebo and enalapril: The studies of left ventricular dysfunctionJournal of the American College of Cardiology, 1994
- Beneficial effects of metoprolol in idiopathic dilated cardiomyopathyThe Lancet, 1993
- Quality of life after myocardial infarction: effect of long term metoprolol on mortality and morbidity.BMJ, 1986